Kura Oncology to Report Second Quarter Financial Results

Kura Oncology announces date for Q2 2026 results, no financials disclosed yet.

Risk flags

• ●Lack of disclosed financial data prevents any assessment of current financial health, profitability, or cash position. This matters because investors cannot gauge near-term or long-term risk exposure until the results are released.
• ●Aspirational language about pipeline and ongoing research is unsupported by evidence or quantifiable milestones. This introduces uncertainty about the pace and likelihood of future product development or revenue growth.
• ●The announcement provides no operational, regulatory, or commercial updates beyond the existence of one FDA-approved product. Absence of such information leaves investors without context on pipeline progress or competitive positioning.

Bottom line

This is a routine notice about the upcoming Q2 2026 financial results release and webcast for Kura Oncology. No financial or operational data are disclosed, so investors cannot assess the company's current performance or outlook from this announcement. The only substantive fact is the continued commercialization of KOMZIFTI® (ziftomenib) for a narrow leukemia indication. All other statements are generic and unsupported by data. This announcement is not actionable until actual results are published; investors should wait for the August 12, 2026 disclosure to evaluate Kura's financial and operational trajectory. The key takeaway is that no new information relevant to investment decisions is provided at this time.

Announcement summary

(NASDAQ:KURA) Kura Oncology, Inc. announced it will report its second quarter 2026 financial results after the close of the U.S financial markets on Wednesday, August 12, 2026. Kura’s management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section. Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia. The company continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition.

Disagree with this article?